Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions

Elsa Shapiro; Jessica Bernstein; Heather R. Adams; Ann J. Barbier; Teresa Buracchio; Peter Como; Kathleen A. Delaney; Florian Eichler; Jonathan C. Goldsmith; Melissa Hogan; Sarrit Kovacs; Jonathan W. Mink; Joanne Odenkirchen; Melissa A. Parisi; Alison Skrinar; Susan E. Waisbren; Andrew E. Mulberg

doi:10.1016/j.ymgme.2016.04.006

Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions

Elsa Shapiro, Jessica Bernstein, Heather R. Adams, Ann J. Barbier, Teresa Buracchio, Peter Como, Kathleen A. Delaney, Florian Eichler, Jonathan C. Goldsmith, Melissa Hogan, Sarrit Kovacs, Jonathan W. Mink, Joanne Odenkirchen, Melissa A. Parisi, Alison Skrinar, Susan E. Waisbren, Andrew E. Mulberg

Research output: Contribution to journal › Comment/debate › peer-review

25 Scopus citations

Abstract

Well-defined and reliable clinical outcome assessments are essential for determining whether a drug provides clinically meaningful treatment benefit for patients. In 2015, FDA convened a workshop, "Assessing Neurocognitive Outcomes in Inborn Errors of Metabolism." Topics covered included special challenges of clinical studies of inborn errors of metabolism (IEMs) and other rare diseases; complexities of identifying treatment effects in the context of the dynamic processes of child development and disease progression; and the importance of natural history studies. Clinicians, parents/caregivers, and participants from industry, academia, and government discussed factors to consider when developing measures to assess treatment outcomes, as well as tools and methods that may contribute to standardizing measures. Many issues examined are relevant to the broader field of rare diseases in addition to specifics of IEMs.

Original language	English (US)
Pages (from-to)	65-69
Number of pages	5
Journal	Molecular Genetics and Metabolism
Volume	118
Issue number	2
DOIs	https://doi.org/10.1016/j.ymgme.2016.04.006
State	Published - Jun 1 2016

Bibliographical note

Funding Information:
An example of ongoing efforts to standardize assessments is the Common Data Elements (CDEs) Project of the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health. This project uses common data elements that apply to multiple fields of research to enable clinical investigators to share information reliably. It facilitates systematic collection, analysis, and sharing of data across research communities. Objectives of the CDE project include: (1) to identify common data elements used in clinical research; (2) to present data elements in standard, widely available formats; (3) to establish common definitions and validate permissible values and ranges to guide researchers in selecting CDEs most applicable to studies; (4) to standardize case report forms and other instruments; and (5) to provide standardized information to researchers for database development. Common data elements can accelerate the pace of clinical research for rare diseases by rendering data more comparable and facilitating multi-center and international efforts [12] . 6.2.2

Publisher Copyright:
© 2016 Published by Elsevier Inc.

Keywords

Clinical outcome assessment
Drug development
Inborn errors
Natural history studies
Neurocognitive
Rare diseases

Access

10.1016/j.ymgme.2016.04.006

http://europepmc.org/articles/pmc4895194

OpenUrl availability

Full text

Cite this

Shapiro, E., Bernstein, J., Adams, H. R., Barbier, A. J., Buracchio, T., Como, P., Delaney, K. A., Eichler, F., Goldsmith, J. C., Hogan, M., Kovacs, S., Mink, J. W., Odenkirchen, J., Parisi, M. A., Skrinar, A., Waisbren, S. E., & Mulberg, A. E. (2016). Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions. Molecular Genetics and Metabolism, 118(2), 65-69. https://doi.org/10.1016/j.ymgme.2016.04.006

Shapiro, E, Bernstein, J, Adams, HR, Barbier, AJ, Buracchio, T, Como, P, Delaney, KA, Eichler, F, Goldsmith, JC, Hogan, M, Kovacs, S, Mink, JW, Odenkirchen, J, Parisi, MA, Skrinar, A, Waisbren, SE & Mulberg, AE 2016, 'Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions', Molecular Genetics and Metabolism, vol. 118, no. 2, pp. 65-69. https://doi.org/10.1016/j.ymgme.2016.04.006

@article{5f31f082a17242c8b21a140d5b662b4b,

title = "Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions",

abstract = "Well-defined and reliable clinical outcome assessments are essential for determining whether a drug provides clinically meaningful treatment benefit for patients. In 2015, FDA convened a workshop, {"}Assessing Neurocognitive Outcomes in Inborn Errors of Metabolism.{"} Topics covered included special challenges of clinical studies of inborn errors of metabolism (IEMs) and other rare diseases; complexities of identifying treatment effects in the context of the dynamic processes of child development and disease progression; and the importance of natural history studies. Clinicians, parents/caregivers, and participants from industry, academia, and government discussed factors to consider when developing measures to assess treatment outcomes, as well as tools and methods that may contribute to standardizing measures. Many issues examined are relevant to the broader field of rare diseases in addition to specifics of IEMs.",

keywords = "Clinical outcome assessment, Drug development, Inborn errors, Natural history studies, Neurocognitive, Rare diseases",

author = "Elsa Shapiro and Jessica Bernstein and Adams, {Heather R.} and Barbier, {Ann J.} and Teresa Buracchio and Peter Como and Delaney, {Kathleen A.} and Florian Eichler and Goldsmith, {Jonathan C.} and Melissa Hogan and Sarrit Kovacs and Mink, {Jonathan W.} and Joanne Odenkirchen and Parisi, {Melissa A.} and Alison Skrinar and Waisbren, {Susan E.} and Mulberg, {Andrew E.}",

note = "Funding Information: An example of ongoing efforts to standardize assessments is the Common Data Elements (CDEs) Project of the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health. This project uses common data elements that apply to multiple fields of research to enable clinical investigators to share information reliably. It facilitates systematic collection, analysis, and sharing of data across research communities. Objectives of the CDE project include: (1) to identify common data elements used in clinical research; (2) to present data elements in standard, widely available formats; (3) to establish common definitions and validate permissible values and ranges to guide researchers in selecting CDEs most applicable to studies; (4) to standardize case report forms and other instruments; and (5) to provide standardized information to researchers for database development. Common data elements can accelerate the pace of clinical research for rare diseases by rendering data more comparable and facilitating multi-center and international efforts [12] . 6.2.2 Publisher Copyright: {\textcopyright} 2016 Published by Elsevier Inc.",

year = "2016",

month = jun,

day = "1",

doi = "10.1016/j.ymgme.2016.04.006",

language = "English (US)",

volume = "118",

pages = "65--69",

journal = "Molecular Genetics and Metabolism",

issn = "1096-7192",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions

AU - Shapiro, Elsa

AU - Bernstein, Jessica

AU - Adams, Heather R.

AU - Barbier, Ann J.

AU - Buracchio, Teresa

AU - Como, Peter

AU - Delaney, Kathleen A.

AU - Eichler, Florian

AU - Goldsmith, Jonathan C.

AU - Hogan, Melissa

AU - Kovacs, Sarrit

AU - Mink, Jonathan W.

AU - Odenkirchen, Joanne

AU - Parisi, Melissa A.

AU - Skrinar, Alison

AU - Waisbren, Susan E.

AU - Mulberg, Andrew E.

N1 - Funding Information: An example of ongoing efforts to standardize assessments is the Common Data Elements (CDEs) Project of the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health. This project uses common data elements that apply to multiple fields of research to enable clinical investigators to share information reliably. It facilitates systematic collection, analysis, and sharing of data across research communities. Objectives of the CDE project include: (1) to identify common data elements used in clinical research; (2) to present data elements in standard, widely available formats; (3) to establish common definitions and validate permissible values and ranges to guide researchers in selecting CDEs most applicable to studies; (4) to standardize case report forms and other instruments; and (5) to provide standardized information to researchers for database development. Common data elements can accelerate the pace of clinical research for rare diseases by rendering data more comparable and facilitating multi-center and international efforts [12] . 6.2.2 Publisher Copyright: © 2016 Published by Elsevier Inc.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Well-defined and reliable clinical outcome assessments are essential for determining whether a drug provides clinically meaningful treatment benefit for patients. In 2015, FDA convened a workshop, "Assessing Neurocognitive Outcomes in Inborn Errors of Metabolism." Topics covered included special challenges of clinical studies of inborn errors of metabolism (IEMs) and other rare diseases; complexities of identifying treatment effects in the context of the dynamic processes of child development and disease progression; and the importance of natural history studies. Clinicians, parents/caregivers, and participants from industry, academia, and government discussed factors to consider when developing measures to assess treatment outcomes, as well as tools and methods that may contribute to standardizing measures. Many issues examined are relevant to the broader field of rare diseases in addition to specifics of IEMs.

AB - Well-defined and reliable clinical outcome assessments are essential for determining whether a drug provides clinically meaningful treatment benefit for patients. In 2015, FDA convened a workshop, "Assessing Neurocognitive Outcomes in Inborn Errors of Metabolism." Topics covered included special challenges of clinical studies of inborn errors of metabolism (IEMs) and other rare diseases; complexities of identifying treatment effects in the context of the dynamic processes of child development and disease progression; and the importance of natural history studies. Clinicians, parents/caregivers, and participants from industry, academia, and government discussed factors to consider when developing measures to assess treatment outcomes, as well as tools and methods that may contribute to standardizing measures. Many issues examined are relevant to the broader field of rare diseases in addition to specifics of IEMs.

KW - Clinical outcome assessment

KW - Drug development

KW - Inborn errors

KW - Natural history studies

KW - Neurocognitive

KW - Rare diseases

UR - http://www.scopus.com/inward/record.url?scp=84964573652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964573652&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2016.04.006

DO - 10.1016/j.ymgme.2016.04.006

M3 - Comment/debate

C2 - 27132782

AN - SCOPUS:84964573652

SN - 1096-7192

VL - 118

SP - 65

EP - 69

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

IS - 2

ER -

Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this